Bladderwrack Fucus vesiculosus Linnaeus, 1753 (marine brown alga; accepted name in WoRMS)
Also called: Fucus, Fucus vesiculosus thallus, kelp (LactMed also uses this name for Fucus)
Bladderwrack is a brown seaweed of North Atlantic coasts; the dried whole alga (thallus) is used in EU traditional herbal medicines for weight loss. It contains iodine, alginic acid and minerals, and can carry heavy metals. Its iodine content drives the main safety concerns.
- Category
- Marine and algae
- Forms
- Thallus (whole dried seaweed), powdered
- Strongest evidence
- C Limited
- Native range
- North Atlantic brown seaweed: WoRMS distribution records include the Arctic, North Sea, Baltic Sea, Celtic Seas, Northwest Atlantic (Gulf of Maine), Azores-Canaries-Madeira and the Mediterranean Sea
- Reviewed
- 2026-10-29
Class 2 Moderately studied in people. No review stating a count was found. This entry cites 4 RCTs of Fucus vesiculosus alone: sources 10-13, a polyphenol-rich extract or 5 g/day dried seaweed versus placebo or a control seaweed, 18 to 38 participants. Its two Ascophyllum-plus-Fucus blend trials are not counted. [10]
Fact-checked 2026-10-29 · How this guide is made
Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.
What research has studied
Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.
A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials
| Topic studied | Grade | What the evidence shows |
|---|---|---|
| Weight loss alongside a reduced-calorie diet (EU traditional use) | C | EMA's herbal committee found clinical evidence insufficient; a study of a combined preparation in obese postmenopausal women had shortcomings, such as an inadequate statistical method, so firm conclusions could not be drawn. [2] |
| Body weight and blood glucose in prediabetes (Ascophyllum plus Fucus extract) | C | A 12-week RCT in 56 overweight or obese prediabetic adults found no effect of 500 mg/day brown-seaweed extract on body weight or blood glucose versus placebo; C-peptide and IL-6 changed slightly. [4] |
| Insulin response to a carbohydrate meal (single dose) | C | In a crossover RCT in 23 adults, 500 mg of an Ascophyllum nodosum and Fucus vesiculosus blend before 50 g of carbohydrate lowered the insulin response by 12.1% but did not change glucose. [5] |
Main constituents: Iodine; soluble fiber (alginic acid); vitamin B12 and iron; may also contain heavy metals such as arsenic, cadmium and lead [1]; European Pharmacopoeia limits for the powder: 0.03% to 0.2% iodine [3]
Amounts studied and limits
Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.
- EU traditional-use monograph (EMA/HMPC, adopted 6 May 2014), adults: powdered thallus 130 mg twice daily with a glass of water, 2 hours before meals; see a doctor if no weight loss after 10 weeks. [3]
- 500 mg/day of an Ascophyllum nodosum and Fucus vesiculosus extract for 12 weeks (prediabetes RCT). [4]
Upper limits
- EU monograph: total iodine intake from Fucus vesiculosus medicinal products should not exceed 400 micrograms per day. [3]
Safety and side effects
- Liver (NIH LiverTox)Nothing found
No published information found in the sources checked.
Details and sources - Pregnancy and breastfeedingEU monograph: safety during pregnancy and lactation has not been established; use is not recommended.
2 statements in the profile.
Details and sources - Interactions with medicines2 listed
Thyroid medicines and iodine preparations; Lithium
Details and sources - Cancer evaluations (IARC, NTP)None found
No IARC or NTP evaluation was found in the lists checked.
Details and sources - FDA new dietary ingredient notificationsNone on FDA's list
FDA does not approve dietary supplements. Each entry is one party's filing.
Details and sources - Dose in official monographsStated
EU (EMA/HMPC monograph, adopted 6 May 2014), traditional use, adults and elderly: powdered herbal substance 130 mg twice daily with a glass of water, …
Details and sources
- Bladderwrack contains iodine, which may be toxic at high doses; EMA advises not exceeding the recommended dose and not combining it with iodine preparations or thyroid medicines. [2]
- EU monograph, overdose: 700 or 1,400 mg daily for several weeks (n=3) increased the intermenstrual period; higher doses can change TSH and may cause acne flare, palpitations, faster heart rate, trembling and blood pressure changes. [3]
- EU monograph: not recommended under 18 years (concerns requiring medical advice); not recommended in pregnancy and breastfeeding because safety has not been established. [3]
- LactMed: iodine is actively transported into breast milk and heavy metals are excreted into milk; some sources recommend against seaweed during breastfeeding. [1]
Interactions
| With | What happens |
|---|---|
| Thyroid medicines and iodine-containing preparations | The EU monograph says they, and other Fucus vesiculosus preparations, should not be taken at the same time. [3] |
| Lithium | The EU monograph cites one published case of hyperthyroidism in a patient with bipolar disorder treated with lithium. [3] |
Tell a pharmacist or doctor about every supplement you take. All documented interactions in this hub.
Identity, quality and standardization
- The EU monograph refers to material complying with the European Pharmacopoeia monograph (01/2008:1426), which sets 0.03%-0.2% iodine; batches should be mixed to respect the daily iodine limit. [3]
- In 77 samples of ten Greenland seaweeds including Fucus vesiculosus, none exceeded EU maximum levels for cadmium, mercury or lead, but some exceeded stricter French limits, especially for cadmium and iodine. [6]
Regulatory status
- EU: an EMA/HMPC monograph (2014) supports traditional herbal medicinal products of powdered bladderwrack as an adjunct to a reduced-calorie diet for weight loss in overweight adults, after serious conditions are excluded. [3]
- US: FDA states that, by law, it does not approve dietary supplements or their labeling before they are marketed; firms are responsible for the safety and labeling of their products. [8]
- US: No NDI notification naming bladderwrack (Fucus vesiculosus) was found in FDA's published NDI list (dated July 9, 2026; checked 2026-10-29). FDA keeps no authoritative list of ingredients marketed before October 15, 1994. [9]
Safety, quality and supply profile
Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.
Compounds responsible
Compounds the sources name as the main or characteristic actives.
US status
What FDA's published records show. FDA does not approve dietary supplements.
- No NDI notification naming bladderwrack (Fucus vesiculosus) was found in FDA's published NDI list (dated July 9, 2026; checked 2026-10-29). FDA keeps no authoritative list of ingredients marketed before October 15, 1994. [P2]
Cancer evaluations (IARC and NTP)
Evaluations name the exact material tested, which may differ from a supplement.
Liver (NIH LiverTox)
- No published information found in the sources checked.
Interactions with medicines
Alcohol
- No published information found in the sources checked.
Interactions with other herbs and supplements
- Other Fucus vesiculosus preparations: Should not be taken concomitantly (EU monograph). [P5]
Adulteration and substitution
- No published information found in the sources checked.
What a certificate of analysis should cover
Tests a quality specification for this material would include, with the reason for each.
- Identity test of the dietary ingredient (at least one appropriate test or examination before use) — 21 CFR 111.75(a)(1)(i) requires identity verification of every component that is a dietary ingredient, unless FDA exempts the firm on petition under 111.75(a)(1)(ii). [P6]
- Iodine content — European Pharmacopoeia powder limits are 0.03%-0.2% iodine, and the EU monograph caps total iodine at 400 micrograms per day. [P5]
- Heavy metals (arsenic, cadmium, lead) — LactMed notes bladderwrack can contain arsenic, cadmium and lead. [P1]
Supply and conservation
- No published information found in the sources checked.
Absorption in people
- No published information found in the sources checked.
Formulations studied to change absorption
Human data only.
- No published information found in the sources checked.
Dose in official monographs
As the monograph states it, for its jurisdiction; not personal advice.
- EU (EMA/HMPC monograph, adopted 6 May 2014), traditional use, adults and elderly: powdered herbal substance 130 mg twice daily with a glass of water, 2 hours before meals, as an adjunct to a reduced-calorie diet; not recommended under 18. [P5]
Sources for this profile
- Drugs and Lactation Database (LactMed). Seaweed (2024 Oct 15) (PMID 30000910), 2024-10-15. ncbi.nlm.nih.gov
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- IARC Monographs. Agents classified by the IARC Monographs (list of classifications, checked 2026-10-29), 2026-10-29. monographs.iarc.who.int
- National Toxicology Program. Technical Reports (list checked 2026-10-29), 2026-10-29. ntp.niehs.nih.gov
- European Medicines Agency, HMPC. Community herbal monograph on Fucus vesiculosus L., thallus, EMA/HMPC/313674/2012 (final, adopted 6 May 2014), 2014-05-06. ema.europa.eu
- eCFR. 21 CFR 111.75 (current as of October 27, 2026), 2026-10-27. ecfr.gov
Sources
- Drugs and Lactation Database (LactMed). Seaweed (2024 Oct 15) (PMID 30000910), 2024-10-15. ncbi.nlm.nih.gov
- European Medicines Agency. Fucus (bladderwrack): herbal summary for the public (first published 02/12/2016), 2016-12-02. ema.europa.eu
- European Medicines Agency, HMPC. Community herbal monograph on Fucus vesiculosus L., thallus, EMA/HMPC/313674/2012 (final, adopted 6 May 2014), 2014-05-06. ema.europa.eu
- Vodouhè M, et al. Marginal impact of brown seaweed Ascophyllum nodosum and Fucus vesiculosus extract on metabolic and inflammatory response in overweight and obese prediabetic subjects. Mar Drugs 2022;20(3):174 (PMID 35323474), 2022-02-26. pubmed.ncbi.nlm.nih.gov
- Paradis ME, Couture P, Lamarche B. A randomised crossover placebo-controlled trial investigating the effect of brown seaweed (Ascophyllum nodosum and Fucus vesiculosus) on postchallenge plasma glucose and insulin levels in men and women. Appl Physiol Nutr Metab 2011;36(6):913-9 (PMID 22087795), 2011-12. pubmed.ncbi.nlm.nih.gov
- Kreissig KJ, et al. Characterisation and chemometric evaluation of 17 elements in ten seaweed species from Greenland. PLoS One 2021;16(2):e0243672 (PMID 33556100), 2021-02-08. pubmed.ncbi.nlm.nih.gov
- WoRMS (World Register of Marine Species). Fucus vesiculosus Linnaeus, 1753, AphiaID 145548: status and distribution records (accessed 2026-10-29), 2026-10-29. marinespecies.org
- U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements (content current as of 08/27/2026), 2026-08-27. fda.gov
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- Murray M, et al. The Impact of a Single Dose of a Polyphenol-Rich Seaweed Extract on Postprandial Glycaemic Control in Healthy Adults: A Randomised Cross-Over Trial. Nutrients 2018;10(3):270 (PMID 29495492), 2018-02-27. pubmed.ncbi.nlm.nih.gov
- Murray M, et al. A Single-Dose of a Polyphenol-Rich Fucus Vesiculosus Extract is Insufficient to Blunt the Elevated Postprandial Blood Glucose Responses Exhibited by Healthy Adults in the Evening: A Randomised Crossover Trial. Antioxidants (Basel) 2019;8(2):49 (PMID 30813480), 2019-02-24. pubmed.ncbi.nlm.nih.gov
- Murray M, et al. Twelve weeks' treatment with a polyphenol-rich seaweed extract increased HDL cholesterol with no change in other biomarkers of chronic disease risk in overweight adults: A placebo-controlled randomized trial. J Nutr Biochem 2021;96:108777 (PMID 34015499), 2021-05-17. pubmed.ncbi.nlm.nih.gov
- Geurts KAM, et al. The Effect of Sargassum fusiforme and Fucus vesiculosus on Continuous Glucose Levels in Overweight Patients with Type 2 Diabetes Mellitus: A Feasibility Randomized, Double-Blind, Placebo-Controlled Trial. Nutrients 2024;16(12):1837 (PMID 38931192), 2024-06-12. pubmed.ncbi.nlm.nih.gov
- A
- Consistent results from several randomized trials or a systematic review of them
- B
- Some positive randomized trials, but small, short, few or inconsistent
- C
- Limited human evidence: single small trials, observational data or mixed results
- D
- Laboratory or animal evidence only; not shown in people
- X
- Well-designed human trials found no meaningful effect
More in marine and algae: Astaxanthin · Carrageenan and agar · Chlorella · Dunaliella · Ecklonia cava · Fucoidan · Kelp and seaweed · Sea moss · All entries A–Z · How to judge a supplement
Health information notice
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.